Article
Gastroenterology & Hepatology
Qiaoyan Liu, Bo Li, Yikang Li, Yiran Wei, Bingyuan Huang, Jubo Liang, Zhengrui You, You Li, Qiwei Qian, Rui Wang, Jun Zhang, Ruiling Chen, Zhuwan Lyu, Yong Chen, Mingxia Shi, Xiao Xiao, Qixia Wang, Qi Miao, Jing-Yuan Fang, Merrill Eric Gershwin, Min Lian, Xiong Ma, Ruqi Tang
Summary: Comparative analysis of gut microbiome and metabolome in IgG4-SC and PSC patients revealed distinct host-microbe interactions that may contribute to disease pathogenesis, highlighting the uniqueness of IgG4-SC.
Article
Gastroenterology & Hepatology
Daniel E. Radford-Smith, Emmanuel A. Selvaraj, Rory Peters, Michael Orrell, Jonathan Bolon, Daniel C. Anthony, Michael Pavlides, Kate Lynch, Alessandra Geremia, Adam Bailey, Emma L. Culver, Fay Probert
Summary: Serum metabolomic profiling has the potential to accurately distinguish between PSC and IgG4-SC, improve the diagnosis of IgG4-RD, and differentiate IgG4-SC from PSC.
LIVER INTERNATIONAL
(2022)
Article
Medicine, General & Internal
Kazuaki Akahoshi, Atsushi Kanno, Tetsurou Miwata, Hiroki Nagai, Kensuke Yokoyama, Eriko Ikeda, Kozue Ando, Kiichi Tamada, Noriyoshi Fukushima, Alan Kawarai Lefor, Hironori Yamamoto
Summary: This case report describes a patient with immunoglobulin G4-related sclerosing cholangitis (IgG4-SC) and concurrent cholangiocarcinoma, with elevated serum IgG4 levels. The patient was diagnosed with cholangiocarcinoma after further examination and biopsy, despite no significant changes on imaging studies.
Article
Health Care Sciences & Services
Jae Keun Park, Dongwuk Kim, Jeong Min Lee, Kwang Hyuck Lee, Kyu Taek Lee, Joo Kyung Park, Jong Kyun Lee
Summary: This study aimed to find the best combinations of serum markers for differentiating IgG4-SC from PSC or CCA. The results showed that serum IgG4/IgG1 or IgG4/(IgG1+IgG3) levels can help differentiate IgG4-SC from PSC, while IgG4 alone is the most accurate marker for differentiating IgG4-SC from CCA.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Medicine, General & Internal
Jong-Sun Kim, Won Ho Choi, Kyung-Ann Lee, Hyun-Sook Kim
Summary: Immunoglobulin G4-related sclerosing cholangitis (IgG4-SC) is an irreversible multi-system fibroin-flammatory disorder that can involve various organs. Prompt diagnosis and appropriate treatment are crucial in managing IgG4-SC, with the need for gradual reduction of glucocorticoid dose and maintenance immunosuppressant therapy to prevent relapse.
WORLD JOURNAL OF CLINICAL CASES
(2021)
Article
Gastroenterology & Hepatology
Takahiro Nakazawa, Terumi Kamisawa, Kazuichi Okazaki, Shigeyuki Kawa, Susumu Tazuma, Takayoshi Nishino, Dai Inoue, Itaru Naitoh, Takayuki Watanabe, Kenji Notohara, Kensuke Kubota, Hirotaka Ohara, Atsushi Tanaka, Hajime Takikawa, Atsushi Masamune, Michiaki Unno
Summary: A new set of clinical diagnostic criteria for IgG4-related sclerosing cholangitis (IgG4-SC) was established by a research group, focusing on six criteria including bile duct narrowing, wall thickening, serological and pathological findings, organ involvement, and steroid therapy effectiveness. These criteria are practical and beneficial for general physicians and non-specialists.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES
(2021)
Article
Medicine, General & Internal
Fuat H. Saner, Alexandra Frey, Bjoern-Ole Stueben, Dieter P. Hoyer, Katharina Willuweit, Martina Daniel, Jassin Rashidi-Alavieh, Jurgen W. Treckmann, Hartmut H. Schmidt
Summary: In this retrospective study of 82 patients who underwent liver transplantation for primary sclerosing cholangitis (PSC), the authors assessed morbidity, survival rates, PSC recurrence, and the impact of donor characteristics in long-term follow-up. The study showed that PSC patients had excellent 10-year survival rates and a lower lab-MELD score was associated with longer survival. Donor characteristics did not affect patient survival.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Sung Hyun Cho, Tae Jun Song, Jin-Seok Park, Jai Hoon Yoon, Min Jae Yang, Seung Bae Yoon, Jae Min Lee, Yun Nah Lee, Seong-Hun Kim, Eun Kwang Choi, Se Woo Park, Dongwook Oh, Do Hyun Park, Sang Soo Lee, Dong-Wan Seo, Sung Koo Lee, Myung-Hwan Kim
Summary: This study compared the clinical outcomes and long-term prognosis of IgG4-related sclerosing cholangitis (IgG4-SC) with proximal bile duct involvement and distal bile duct involvement. The two groups showed significant differences in terms of steroid-responsiveness, occurrence of liver cirrhosis, and recurrence. Determining therapeutic and follow-up strategies based on the location of bile duct involvement may be advantageous.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Medical Laboratory Technology
Osman Yilmaz, Karen Pinto, Vikram Deshpande
Summary: The pancreatobiliary tract has heterogeneous fibroinflammatory conditions that may be immune-mediated or a reaction to neoplasm, leading to overlap between inflammatory and neoplastic lesions. Autoimmune pancreatitis types 1 and 2 and immunoglobulin G4-related sclerosing cholangitis require a multimodal approach for diagnosis, relying on clinical, radiographic, serologic, histopathologic, and immunohistochemical correlation.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
(2023)
Review
Gastroenterology & Hepatology
Itaru Naitoh, Takahiro Nakazawa
Summary: IgG4-related sclerosing cholangitis (IgG4-SC) can be diagnosed based on cholangiographic classification and clinical diagnostic criteria, with a close association with autoimmune pancreatitis (AIP). In Japan, the 2020 clinical diagnostic criteria have been established, including narrowing of the intrahepatic and/or extrahepatic bile duct, thickening of the bile duct wall, serological and pathological findings, among others.
Article
Gastroenterology & Hepatology
Yusuke Kurita, Yuji Fujita, Yusuke Sekino, Seitaro Watanabe, Akito Iwasaki, Koichi Kagawa, Emiko Tanida, Shin Yagi, Sho Hasegawa, Takamitsu Sato, Kunihiro Hosono, Shingo Kato, Noritoshi Kobayashi, Yasushi Ichikawa, Itaru Endo, Atsushi Nakajima, Kensuke Kubota
Summary: The study found that IgG4-SC patients have a higher risk of cancer, including pancreatic and bile duct cancer. The risk of cancer is particularly high within the first five years after diagnosis.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Taotao Zhou, Henrike Lenzen, Leona Dold, Bennet Bundgens, Heiner Wedemeyer, Michael P. Manns, Maria A. Gonzalez-Carmona, Christian P. Strassburg, Tobias J. Weismuller
Summary: Patients with PSC and elevated sIgG4 should be considered as a distinct subgroup, characterized by different clinical and cholangiographical features and are associated with an inferior outcome.
LIVER INTERNATIONAL
(2021)
Article
Medicine, General & Internal
Anass Nadi, Yassamin Benhayoun, Reda Cherkaoui, Hanane Delsa, Fedoua Rouibaa
Summary: This study observed three cases of IgG4-related disease involving the biliary tract and pancreas. The clinical presentation and treatment response of this disease were found to be heterogeneous, and there are still many unresolved questions. Further research is needed to better manage this disease.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2022)
Article
Pediatrics
Mohana Sathiaseelan, Rishi Bolia, Raychel Barallon, George Alex, Winita Hardikar, Jeremy Rajanayagam
Summary: Primary sclerosing cholangitis (PSC) is a chronic progressive cholestatic disorder associated with ulcerative colitis (UC). This study aimed to evaluate the effects of UC on liver-related outcomes in children with PSC. The results showed that children with UC were more likely to have complications of PSC, and there was an inverse correlation between the severity of UC and PSC severity in children with concurrent PSC-UC.
JOURNAL OF PAEDIATRICS AND CHILD HEALTH
(2022)
Article
Gastroenterology & Hepatology
Damjana Bogatic, Robert Bryant, Kate D. Lynch, Samuel P. Costello
Summary: Primary sclerosing cholangitis (PSC) is a progressive liver disease with poor prognosis and no effective therapies to prevent progression. This study evaluated potential medical therapies that may exert their effects in PSC by modulation of the gut-liver axis.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)